COVID-19 antibody treatment credited for relieving hospitals

NASHVILLE, Tenn. (WKRN)– Jeffrey Caruth credits an investigational treatment called Monoclonal Antibodies for helping him recover from COVID-19.

“I feel that if I hadn’t gotten that treatment, I’m afraid of the possibilities of what could have happened,” says Caruth.

Sick and quarantined, he struggled to breathe.

“It just scares you, you know? It’s not something normal that you really have in your life.”
 
Praying for relief, he traveled to Vanderbilt where he was hooked to an IV for an hour receiving laboratory-made antibodies that target and neutralizes the SARS-CoV-2 virus known as COVID-19.

“I didn’t feel like anything progressed,” Caruth explains. “I felt like I was at the same, which made me happy. And then, as another day went by, I was feeling a little bit better.”

Caruth, like so many others considered high-risk, experienced an improved outcome following treatment. In fact, data shows 97% of those who received the

Read More

Paris Regional Medical Center offering monoclonal antibody treatment for Covid-19 patients | Free

Paris Regional Medical Center announced today that it is offering both bamlanivimab/casirivimab and imdevimab, new monoclonal antibody therapies, for treatment of non-hospitalized patients with a mild or moderate case of Covid-19.

Developed by pharmaceutical companies Eli Lilly/Regeneron Pharmaceuticals Inc., the drug recently received emergency use authorization from the Food and Drug Administration and is now being allocated by the U.S. Department of Health and Human Services in partnership with the Texas Department of State Health Services and other state agencies.

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful viruses. Bamlanivimab/casirivimab and imdevimab are specifically designed to help block the SARS-CoV-2 virus and prevent the virus from further infecting healthy cells. Administered intravenously, this innovative treatment is designed to help lessen the severity of Covid-19 in individuals who test positive and are at risk for developing a severe form of the disease.

“Paris Regional

Read More